PFD and LIR combination therapy demonstrates superior therapeutic efficacy in treating BDL-induced LF through enhanced liver regeneration through enhanced expression of proliferative and differentiation markers and modulation of autophagy and NLRP3 inflammasome pathways, indicating that the combination of PFD and LIR represents a promising therapeutic strategy for LF. The gene discussed is NLRP3; the disease is Lassa fever.